Bapineuzumab

[Riverwild]

Today Elan Pharmaceuticals and Wyeth announced that they will begin phase III clinical trials on Bapineuzumab for Alzheimers disease based on the data seen at midpoint PII trials. The data seen has not been released and will not be until PII is concluded but this is almost 6 months before the PII trial is over!!

Whatever they saw MUST be GOOD!!!